Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
IRWD Stock Chart & Stats
$4.61
<$0.01(0.11%)
At close: 4:00 PM EST
$4.61
<$0.01(0.11%)
Day’s Range― - ―
52-Week Range$0.53 - $5.78
Previous CloseN/A
Volume359.32K
Average Volume (3M)5.73M
Market Cap
$749.95M
Enterprise Value$1.19B
Total Cash (Recent Filing)$140.41M
Total Debt (Recent Filing)$598.24M
Price to Earnings (P/E)29.9
Beta0.56
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding162,678,650
10 Day Avg. Volume2,289,265
30 Day Avg. Volume5,730,109
Financial Highlights & Ratios
PEG Ratio-8.00
Price to Book (P/B)-2.34
Price to Sales (P/S)2.01
P/FCF Ratio6.82
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda8.10
Forecast
1Y Price Target
$6.23Price Target Upside35.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceManagement expects the rest of the year to show similar strength as 2Q, with guidance for $260-290M total revenue and adjusted EBITDA greater than $105M reiterated.
Revenue GrowthPrescription demand growth continues to be strong with IRWD highlighting 8% y/y volume growth in 1Q25.
Bears Say
Debt And Financial UncertaintyThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Regulatory ChallengesThe FDA requires another confirmatory Phase 3 trial for Apraglutide to validate its efficacy and match previous exposure levels.
Ironwood Pharma News
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $0.53 and its highest was $5.78 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is $749.95M.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is May 13, 2026 which is in 87 days.
How were Ironwood Pharma’s earnings last quarter?
Currently, no data Available
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma does not currently pay dividends.
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 162,678,650 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ironwood Pharma?
Currently, no hedge funds are holding shares in IRWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ironwood Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.23 (35.14% Upside)
$6.23 (35.14% Upside)
Blogger Sentiment
Bullish
IRWD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 191.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.4%
Last 30 Days ▲ 47.1%
Last 30 Days ▲ 47.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.68%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IRWD Stock 12 Month Forecast
Average Price Target
$6.23
▲(35.14% Upside)
Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Ownership Overview
13.03% Insiders
14.24% Mutual Funds
0.51% Other Institutional Investors
55.78% Public Companies and
Individual Investors